AST5902 trimesylate

Cat. No.: HY-138627A

CAS No.: 2929417-90-1

Molecular Formula: $C_{30}H_{41}F_3N_8O_{11}S_3$

Molecular Weight: 842.88

Target: EGFR; Drug Metabolite

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Metabolic Enzyme/Protease

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (59.32 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.1864 mL	5.9320 mL	11.8641 mL
	5 mM	0.2373 mL	1.1864 mL	2.3728 mL
	10 mM	0.1186 mL	0.5932 mL	1.1864 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an EGFR inhibitor[1].

IC_{50} & Target

EGFR[1]

REFERENCES

[1]. Xiao-yun Liu, et al. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin. 2020 Oct; 41(10): 1366-1376.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA